Perugia

• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi … Recruiting
  2023-509851-15-00 5 2024-10-22 Colon cancer
• 202301CPC Redefine-HF Recruiting
  2023-508581-15-00 5 2024-10-08 Heart condition
• HARMONi-3 Recruiting
  2024-513087-26-00 5 2024-09-10 Metastatic Non-small Cell Lung Cancer
• A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro … Recruiting
  2023-508005-24-00 5 2024-08-01 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting
  2024-511959-18-01 5 2024-07-01 Acute Pulmonary Embolism
• A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF … Recruiting
  2022-502092-33-00 4 2024-05-31 Extensive-disease small cell lung cancer and high SLFN11-expression
• Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting
  2024-511397-70-00 4 2024-05-06 metastatic renal cell carcinoma (mRCC)
• Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting
  2023-504044-34-00 4 2024-04-17 Untreated Chronic Lymphocytic Leukemia
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based c … Recruiting
  2023-506714-43-00 4 2024-03-15 ALK positive Non-Small Cell Lung Cancer
• An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi … Recruiting
  2022-501453-36-00 5 2024-02-23 Breast cancer
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• A Phase 1/2 study of Enzomenib (DSP-5336) in Adult Patients with Acute leukemia Recruiting
  2022-502741-10-00 7 2024-01-26 Acute Leukemia with Mixed Lineage Leukemia (MLL)-rearrangement or Nucl
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 Relapsed/Refractory Follicular Lymphoma
• Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting
  2022-502775-29-01 5 2023-12-14 Early stage Follicular Lymphoma
• Evaluaton of ibrutinib therapy for the treatment of autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocy … Recruiting
  2023-509793-38-00 4 2023-11-24 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like mo
• Tebentafusp Regimen Versus Investigator’s Choice in Previously Treated Advanced Melanoma (TEBE-AM) Recruiting
  2022-502732-39-00 10 2023-09-01 Previously treated non-ocular advanced melanoma
• First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl- … Recruiting
  2023-510431-11-00 4 2023-07-21 Chronic Lymphocytic Leukemia
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke
• A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting
  2022-500967-11-00 5 2023-07-06 Previously Untreated Metastatic or Unresectable Melanoma
• "APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIA … Recruiting
  2022-501894-37-00 4 2023-03-02 prostate cancer
• phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate … Recruiting
  2024-511631-10-00 9 2023-02-27 Hodgkin’s lymphoma

Showing 97–120 of 270 trials